Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$14.01 +0.4%	$16.64	$3.22 ▼ $21.48	$374.37M	1.28	251,127 shs	4.39 million shs
IGNY Ignyte Acquisition		$1.91	$8.62 ▼ $15.00	$95.00M	0.19	26,174 shs	177,600 shs
SLDB Solid Biosciences	$4.72 -1.9%	$3.68	$2.41 ▼ $10.37	$372.85M	2.22	1.20 million shs	7.02 million shs
TECX Tectonic Therapeutic	$19.80 -1.3%	$21.22	$13.70 ▼ $61.07	$374.66M	3.25	182,787 shs	1.66 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	+0.36%	+3.24%	-30.23%	+7.60%	+316.96%
IGNY Ignyte Acquisition	0.00%	0.00%	0.00%	0.00%	+135,837.50%
SLDB Solid Biosciences	-1.87%	-1.46%	+44.79%	+9.26%	-17.19%
TECX Tectonic Therapeutic	-1.35%	-0.05%	-8.12%	+6.17%	+24.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.5876 of 5 stars	3.5	3.0	0.0	0.0	2.0	1.7	0.6
IGNY Ignyte Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	3.2786 of 5 stars	4.6	2.0	0.0	0.0	2.1	1.7	0.6
TECX Tectonic Therapeutic	3.0888 of 5 stars	3.7	1.0	0.0	0.0	1.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	111.75% Upside
IGNY Ignyte Acquisition	0.00	N/A	N/A	N/A
SLDB Solid Biosciences	3.17	Buy	$15.10	219.92% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	322.22% Upside

Current Analyst Ratings Breakdown

Latest IGNY, TECX, ETON, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$39.01M	9.63	N/A	N/A	$0.94 per share	14.90
IGNY Ignyte Acquisition	N/A	N/A	N/A	N/A	($0.28) per share	N/A
SLDB Solid Biosciences	$8.09M	45.22	N/A	N/A	$3.43 per share	1.38
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.02	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
IGNY Ignyte Acquisition	-$490K	N/A	0.00	N/A	N/A	N/A	365.46%	-0.83%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)

Latest IGNY, TECX, ETON, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IGNY Ignyte Acquisition	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
IGNY Ignyte Acquisition	N/A	0.14	0.14
SLDB Solid Biosciences	N/A	10.89	10.89
TECX Tectonic Therapeutic	N/A	22.92	22.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
IGNY Ignyte Acquisition	61.08%
SLDB Solid Biosciences	81.46%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	16.03%
IGNY Ignyte Acquisition	19.90%
SLDB Solid Biosciences	1.90%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
IGNY Ignyte Acquisition	3	7.28 million	5.83 million	Not Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	11.58 million	N/A

IGNY, TECX, ETON, and SLDB Headlines

Recent News About These Companies

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25 at 3:23 AM | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Rating Lowered to "Sell" at Wall Street Zen

June 22, 2025 | americanbankingnews.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Raymond James

June 11, 2025 | marketbeat.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

Tectonic Therapeutic (NASDAQ:TECX) Given Average Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded at Lifesci Capital

June 7, 2025 | marketbeat.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Lifesci Capital Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)

June 6, 2025 | marketbeat.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

Millennium Management LLC Invests $1.33 Million in Tectonic Therapeutic (NASDAQ:TECX)

June 4, 2025 | marketbeat.com

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

May 17, 2025 | quiverquant.comQ

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

May 17, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

IGNY, TECX, ETON, and SLDB Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$14.01 +0.05 (+0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$14.03 +0.02 (+0.14%)

As of 06/27/2025 05:50 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Ignyte Acquisition NASDAQ:IGNY

Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.

Solid Biosciences NASDAQ:SLDB

$4.72 -0.09 (-1.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.83 +0.11 (+2.33%)

As of 06/27/2025 07:44 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Tectonic Therapeutic NASDAQ:TECX

$19.80 -0.27 (-1.35%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$19.80 0.00 (-0.03%)

As of 06/27/2025 07:29 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time